B-Phage is a Cape Town–based biotechnology startup developing next-generation bacteriophage-based therapeutics to address the global antimicrobial resistance (AMR) crisis by harnessing natural viruses that selectively target and kill pathogenic bacteria. The company builds and curates a proprietary library of bacteriophages (B-PhageBank™) and uses AI-driven platforms such as AlphaPhage™ to match phages to bacterial pathogens quickly and precisely, accelerating discovery and development of targeted phage therapies. B-Phage’s lead programs focus on combating drug-resistant infections, with scalable platforms designed to support preclinical and clinical development pipelines that blend biological science, machine learning and data-driven processes to create effective, targeted antimicrobial solutions.
